LIPTIDE - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 79243223
Serial Number
79243223
Registration Number
6039104
Word Mark
LIPTIDE
Status
700 - Registered
Status Date
2020-04-28
Filing Date
2018-07-30
Registration Number
6039104
Registration Date
2020-04-28
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2020-02-11
Attorney Name
Thomas W. Cole
Law Office Assigned Location Code
L70
Employee Name
COLLOPY, DIANE PATRICI
Statements
Goods and Services
Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-10-19
Primary Code
005
Current Trademark Owners
Party Name
Nanogenics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company).
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Nanogenics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company).
Address
Please log in with your Justia account to see this address.
Party Name
Nanogenics Limited
Party Type
20 - Owner at Publication
Legal Entity Type
99 - Other (Limited Company).
Address
Please log in with your Justia account to see this address.
Party Name
Nanogenics Limited
Party Type
10 - Original Applicant
Legal Entity Type
99 - Other (Limited Company).
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Thomas W. Cole
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1428875
International Registration Date
2018-07-30
International Publication Date
2018-10-18
International Renewal Date
2028-07-30
Auto Protection Date
2020-04-18
International Status
001 - Request for extension of protection established
International Status Date
2018-10-18
Priority Claimed In
True
Priority Claimed Date
2018-07-02
First Refusal In
True
Trademark Events
Event DateEvent Description
2018-10-18SN ASSIGNED FOR SECT 66A APPL FROM IB
2018-10-19NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2018-10-23APPLICATION FILING RECEIPT MAILED
2018-11-15ASSIGNED TO EXAMINER
2018-11-23NON-FINAL ACTION WRITTEN
2018-11-24NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2018-12-07REFUSAL PROCESSED BY MPU
2018-12-07NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2018-12-28REFUSAL PROCESSED BY IB
2019-04-11NEW REPRESENTATIVE AT IB RECEIVED
2019-05-29TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-06-03ASSIGNED TO LIE
2019-06-07CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-06-07TEAS/EMAIL CORRESPONDENCE ENTERED
2019-06-28FINAL REFUSAL WRITTEN
2019-06-28FINAL REFUSAL E-MAILED
2019-06-28NOTIFICATION OF FINAL REFUSAL EMAILED
2019-12-26TEAS REQUEST FOR RECONSIDERATION RECEIVED
2019-12-26CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-12-26TEAS/EMAIL CORRESPONDENCE ENTERED
2020-01-03APPROVED FOR PUB - PRINCIPAL REGISTER
2020-01-22NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2020-01-22NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
2020-01-22NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2020-02-07NOTIFICATION PROCESSED BY IB
2020-02-11PUBLISHED FOR OPPOSITION
2020-02-11OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-03-18NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
2020-03-18NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
2020-04-03NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
2020-04-28REGISTERED-PRINCIPAL REGISTER
2020-07-28FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2020-09-05FINAL DISPOSITION PROCESSED
2020-09-08FINAL DISPOSITION NOTICE SENT TO IB
2020-09-26FINAL DECISION TRANSACTION PROCESSED BY IB